Fu, Y., Lin, H., Ou, Y., Wu, C., & Fu, H. Bevacizumab as a mitigating factor for the impact of high systemic immune-inflammation index on chemorefractory in advanced epithelial ovarian cancer. BMC.
Chicago Style (17th ed.) CitationFu, Yan-Ping, Hao Lin, Yu-Che Ou, Chen-Hsuan Wu, and Hung-Chun Fu. Bevacizumab as a Mitigating Factor for the Impact of High Systemic Immune-inflammation Index on Chemorefractory in Advanced Epithelial Ovarian Cancer. BMC.
MLA (9th ed.) CitationFu, Yan-Ping, et al. Bevacizumab as a Mitigating Factor for the Impact of High Systemic Immune-inflammation Index on Chemorefractory in Advanced Epithelial Ovarian Cancer. BMC.
Warning: These citations may not always be 100% accurate.